Unknown

Dataset Information

0

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.


ABSTRACT: Objectives: Describe the safety and tolerability of lisdexamfetamine dimesylate (LDX) and provide data on clinical effects for efficacy-related endpoints and pharmacokinetics in preschool-aged children with attention-deficit/hyperactivity disorder (ADHD). Methods: This phase 2, multicenter, open-label, dose-optimization study (ClinicalTrials.gov registry: NCT02402166) was conducted at seven U.S. sites between April 15, 2015, and June 30, 2016. Children (4-5 years of age) meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for ADHD and having ADHD Rating Scale-IV Preschool version (ADHD-RS-IV-PS) total scores ?28 (boys) or ?24 (girls) were eligible. Open-label LDX (8-week duration) was initiated at 5?mg and titrated to 30?mg until achieving an optimal dose. Assessments included treatment-emergent adverse events (TEAEs), vital sign changes, ADHD-RS-IV-PS total score changes, and pharmacokinetic evaluations. Results: Among 24 participants, the most frequently reported TEAE was decreased appetite (8/24; 33%). At week 8/early termination, mean (standard deviation) systolic and diastolic blood pressure and pulse changes from baseline were -1.1 (7.31) and 1.5 (6.93) mmHg and -0.8 (12.75) bpm, respectively. The mean (95% confidence interval) change from baseline ADHD-RS-IV-PS total score at the final on-treatment assessment was -26.1 (-32.2 to -20.0). Pharmacokinetic parameters of d-amphetamine, a major active metabolite of LDX, were characterized: d-amphetamine exposure increased with LDX dose; mean tmax and t1/2, respectively, ranged from 4.00 to 4.23 hours and 7.18 to 8.46 hours. Conclusions: In preschool-aged children with ADHD, LDX was generally well tolerated and reduced ADHD symptoms, consistent with observations in children 6-17 years of age. Based on these findings, a starting LDX dose as low as 5?mg in phase 3 studies in preschool-aged children is supported.

SUBMITTER: Childress AC 

PROVIDER: S-EPMC7153646 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.

Childress Ann C AC   Findling Robert L RL   Wu James J   Kollins Scott H SH   Wang Yi Y   Martin Patrick P   Robertson Brigitte B  

Journal of child and adolescent psychopharmacology 20200211 3


<b><i>Objectives:</i></b> Describe the safety and tolerability of lisdexamfetamine dimesylate (LDX) and provide data on clinical effects for efficacy-related endpoints and pharmacokinetics in preschool-aged children with attention-deficit/hyperactivity disorder (ADHD). <b><i>Methods:</i></b> This phase 2, multicenter, open-label, dose-optimization study (ClinicalTrials.gov registry: NCT02402166) was conducted at seven U.S. sites between April 15, 2015, and June 30, 2016. Children (4-5 years of a  ...[more]

Similar Datasets

| S-EPMC2732626 | biostudies-literature
| S-EPMC3398683 | biostudies-literature
| S-EPMC2704174 | biostudies-literature
| S-EPMC3225298 | biostudies-literature
| S-EPMC4818045 | biostudies-literature
| S-EPMC5843702 | biostudies-literature
| S-EPMC3918120 | biostudies-literature
| S-EPMC5976689 | biostudies-literature
| S-EPMC3022598 | biostudies-literature
| S-EPMC5773633 | biostudies-literature